A multicenter, open-label, phase I study evaluating the safety and tolerability of intravenous pegaspargase in combination with intravenous gemcitabine HCl in the treatment of advanced and/or metastatic solid tumors and lymphoma

Trial Profile

A multicenter, open-label, phase I study evaluating the safety and tolerability of intravenous pegaspargase in combination with intravenous gemcitabine HCl in the treatment of advanced and/or metastatic solid tumors and lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 May 2015

At a glance

  • Drugs Gemcitabine; Pegaspargase
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Enzon Pharmaceuticals
  • Most Recent Events

    • 08 May 2008 Status changed from recruiting to discontinued, according to an Enzon media release.
    • 18 Aug 2006 Status change
    • 03 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top